

Erratum

Erratum to: Remon J, Passiglia F, Myung-Ju A, et al. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. *J Thorac Oncol.* 2020;15(6):914-947.

The authors wish to replace the published figure 2 and table 3 with these below. The original table and figure had regrettable errors.




Figure 2. Ongoing phase III trials with adjuvant immune checkpoint inhibitor (ICI). ACT, adjuvant chemotherapy; DFS, disease-free survival; ITT, intention to treat; OS, overall survival; PD-L1, programmed death ligand-1; PS, performance status; Q2W, every 2 weeks; Q3W, every 3 weeks; 1 y, 1 year.

Table 3. Ongoing clinical trials with neoadjuvant immune checkpoint inhibitors with or without chemotherapy

Trial	NCT	Drug	Stage	Target Accrual	Phase	Endpoint
MK3475-223	NCT 02938624	Pembrolizumab different dose / regimens → S	I-II	28	I	Toxicity, MPR
TOP 1501	NCT 02818920	Pembrolizumab (200 mg) x 2 cycles → S → Pembrolizumab (200 mg) x 4 cycles	IB-IIIa	32	II	Surgical feasibility
PRICNEPS	NCT 02994576	Atezolizumab (1200 mg) x 1 cycle → S	IA-IIIa (no N2)	60	II	Toxicity
SAKK 16/14	NCT 02572843	CT x 2 → Durvalumab (750 mg) x 2 cycles → Durvalumab (750 mg) x 1 year	IIIa (N2)	68	II	EFS
IONESCO	NCT 03030131	Durvalumab (750 mg) Q2W x 3 cycles → S	IB-II	81	II	R0 resection
CANOPY N	NCT 03968419	Canakinumab or pembrolizumab (200 mg) or Canakinumab + Pembrolizumab x 2 cycles → S	IB-IIIa	110	II	MPR
KEYNOTE 617	NCT 03425643	CT + Pembrolizumab (200 mg) / placebo x 4 cycles → S → Pembrolizumab / Placebo x 13 cycles	IIB-IIIa	786	III	EFS, OS
CheckMate 816*	NCT 02998528	CT + Nivolumab (360 mg) x 3 cycles → S vs. CT x 3 cycles → S	IB-IIIa	350	III	EFS, MPR
IMpower 030	NCT 03456063	CT + Atezolizumab (1200 mg) / placebo x 4 cycles → S → Atezolizumab / Placebo x 16 cycles	II-IIIb (cT3N2)	374	III	MPR
AEGEAN	NCT 03800134	CT + Durvalumab (1500 mg) / Placebo Q3W x 4 cycles → S → Durvalumab / Placebo Q4W x 12 cycles	IIa-IIIb	300	III	MPR